Loading stock data…
BRTX
$0.39+0.03 (+8.95%)
After Hours$0.39-0.00 (-1.09%)· Last close Jun 9
BioRestorative Therapies, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioRestorative Therapies, Inc. in the Healthcare sector is trading at $0.39 with a market capitalization of $10M. Wall Street consensus targets $8.00 (2 analysts), implying a +1928.4% move over the next 12 months. The stock is currently near its 52-week low of $0.16, remaining 55.7% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +1928.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$0.39
Potential Downside
0%
Whystock Fair Value$0.39
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disord...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.05M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-365.43%
Volume
Today's trading volume
998,638
Recent News
Sector Update: Healthcare Stocks Decline Tuesday Afternoon
Healthcare stocks were lower Tuesday afternoon, with the NYSE Healthcare Index shedding 0.6% and the
What Makes Biorestorative Therapies (BRTX) a New Buy Stock
Biorestorative Therapies (BRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of +36.67% and -53.66%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -38.89% and -14.37%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +93.35% and +16.63%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?